# reload+after+2024-01-23 16:40:12.517634
address1§Alderley Park
address2§Block 33 Mereside Alderley Edge
city§Macclesfield
zip§SK10 4TG
country§United Kingdom
phone§44 16 2546 9900
website§https://www.redxpharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops RXC008, a gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the RAS-RAF-MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.
fullTimeEmployees§65
companyOfficers§[{'maxAge': 1, 'name': 'Ms. Lisa Mary Whewell Anson', 'age': 53, 'title': 'CEO & Executive Director', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 636994, 'exercisedValue': 0, 'unexercisedValue': 822256}, {'maxAge': 1, 'name': 'Mr. Peter J. Collum', 'title': 'Chief Financial Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. James  Mead', 'age': 45, 'title': 'Chief Operating Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 132671, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Richard  Armer', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Karl  Hard Ph.D.', 'age': 61, 'title': 'Head of Investor Relations', 'yearBorn': 1962, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Claire  Solk', 'title': 'General Counsel & Company Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Caitlin  Pearson', 'title': 'Head of Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jane  Robertson', 'title': 'Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Cliff  Jones', 'title': 'Senior Vice President of Chemistry, DMPK & Intellectual Property', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Caroline  Phillips', 'title': 'Senior Vice President of Biology', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§-0.521
priceToSalesTrailing12Months§20.365759
currency§GBp
forwardEps§-8.1
exchange§LSE
quoteType§EQUITY
shortName§REDX PHARMA PLC ORD 1P
longName§Redx Pharma Plc
firstTradeDateEpochUtc§1427443200
timeZoneFullName§Europe/London
timeZoneShortName§GMT
uuid§bbc071ef-6450-3b80-91f7-760ae0cba49d
targetHighPrice§125.0
targetLowPrice§125.0
targetMeanPrice§125.0
targetMedianPrice§125.0
recommendationKey§none
numberOfAnalystOpinions§1
quickRatio§1.109
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
